
P/E Ratio: Price to Earnings - Most used valuation metric
Analyzing Investment Quality
Processing 9 key metrics...
Loading shareholding data...
No insider trading data available
Standard pivot points - most widely used
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹3254.50 | +₹469.40 | +16.85% |
| R3 | ₹3066.60 | +₹281.50 | +10.11% |
| R2 | ₹2972.30 | +₹187.20 | +6.72% |
| R1 | ₹2878.70 | +₹93.60 | +3.36% |
| PIVOT | ₹2784.40 | -0.70 | -0.03% |
| CURRENT | ₹2785.10 | - | - |
| S1 | ₹2315.00 | -₹470.10 | -16.88% |
| S2 | ₹2502.90 | -₹282.20 | -10.13% |
| S3 | ₹2596.50 | -₹188.60 | -6.77% |
| S4 | ₹2690.80 | -₹94.30 | -3.39% |
is trading CPR, indicating
CPR is
Day's range: ~
Trading Inside opening range
| Company Name |
|---|
Amrutanjan Health Care Ltd |
Anuh Pharma Ltd |
Bajaj Healthcare Ltd |
Beta Drugs Ltd |
Bliss GVS Pharma Ltd |
Indoco Remedies Ltd |
Ind-Swift Laboratories Ltd |
Jagsonpal Pharmaceuticals Ltd |
Kopran Ltd |
Lincoln Pharmaceuticals Ltd |
Morepen Laboratories Ltd |
Sakar Healthcare Ltd |
Sigachi Industries Ltd |
Sun Pharmaceutical Industries Ltd |
Syncom Formulations (India) Ltd |
Themis Medicare Ltd |
TTK Healthcare Ltd |
Venus Remedies Ltd |
Wanbury Ltd |

301, E Square,, Subhash Road,, Vile Parle East.
Mumbai
MAHARASHTRA
IN
Tel: 912240842222
Website:https://www.nglfinechem.com/
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 682
IPO Date: 20/12/1994
Mr. Rajesh Lawande
Chief Financial Officer, Whole Time Director
Mrs. Pallavi Pednekar
Compliance Officer, Company Secretary
Mr. Rahul Nachane
Managing Director, Director
Mr. Dhananjay Mungale
Additional Non-Executive Director
Ms. Ajita Nachane
Non-Executive Director
Mr. Sudhir Deo
Additional Non-Executive Independent Director
Ms. Sarala Menon
Non-Executive Woman Independent Director
Mr. Jayaram Sitaram
Non-Executive Independent Director
Get answers to the most common questions about NGL Fine Chem Ltd stock price, fundamentals, financial metrics, and investment analysis
Peers, sector trends, screeners and strategy playbooks contextual to this stock.